SPC Financial Inc. Acquires 550 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

SPC Financial Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 5,530 shares of the biopharmaceutical company’s stock after buying an additional 550 shares during the period. SPC Financial Inc.’s holdings in Gilead Sciences were worth $464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $25,328,000. Legal & General Group Plc lifted its position in Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Gilead Sciences during the first quarter worth approximately $462,000. Brookstone Capital Management grew its position in shares of Gilead Sciences by 751.1% in the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock valued at $9,322,000 after purchasing an additional 112,305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Gilead Sciences by 13.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 33,162 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock worth $3,033,340 in the last 90 days. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday. They issued an “outperform” rating and a $105.00 target price for the company. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a research report on Monday, July 8th. Wells Fargo & Company upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 9th. Ten equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.37.

Gilead Sciences Stock Up 0.7 %

GILD stock opened at $87.36 on Friday. The firm has a 50-day moving average price of $80.80 and a 200-day moving average price of $72.71. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $108.84 billion, a P/E ratio of 242.67, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.53%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.